Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Partially Remote

Drugs

Locations

Clinical Specialty

601-620 of 998 trials

X-Linked Hypohidrotic Ectodermal Dysplasia: ER004 Treatment

We are studying a new prenatal treatment for male infants with X-linked hypohidrotic ectodermal dysplasia to see if it improves sweating ability and dental health. The trial also examines the safety of this treatment for both the infants and their mothers.

X-linked Hypohidrotic Ectodermal Dysplasia≤3 monthsEfficacy phase (II)≤5 visits No Placebo Investigational Medicines Cost Reimbursement Partially RemoteDermatologyInternal MedicinePediatrics

Crohn's Disease: SAR441566 Treatment Study

We are investigating how different doses of SAR441566 affect symptoms and health in adults with moderate to severe Crohn's disease. This study aims to find out if the medication can help improve patients' quality of life and overall condition.

Crohn's Disease1-2 yearsEfficacy phase (II)16-20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteGastroenterologyInternal Medicine

Sickle Cell Disease and β-Thalassemia: CTX001 Treatment Study

We are studying the long-term safety and effectiveness of a new CRISPR-based treatment for patients with β-thalassemia or severe sickle cell disease. This research aims to understand how well the treatment works over time.

Sickle Cell DiseaseTransfusion Dependent ThalassemiaConfirmation phase (III)No Placebo Standard Medicines Cost Reimbursement Partially RemoteHematology

Advanced Melanoma: EIK1001 and Pembrolizumab Study

We are studying a new treatment combining EIK1001 with pembrolizumab for patients with advanced melanoma. The goal is to see if this combination improves survival and slows disease progression compared to a placebo.

Advanced Melanoma1-2 yearsEfficacy phase (II)Confirmation phase (III)Investigational Medicines Partially RemoteOncology

BCR-ABL1+ Chronic Myeloid Leukemia: Asciminib Treatment Study

We are studying Asciminib, alone or with Nilotinib, for adults with BCR-ABL1+ Chronic Myeloid Leukemia. The goal is to see if this treatment helps achieve better disease control and improves quality of life.

Chronic Myeloid Leukemia>2 yearsEfficacy phase (II)No Placebo Standard Medicines Partially RemoteHematologyOncology

Systemic Juvenile Idiopathic Arthritis: Sarilumab Study

We are testing the medication sarilumab in children and adolescents with systemic juvenile idiopathic arthritis to find the best dose and understand its effects and safety.

Systemic Juvenile Idiopathic Arthritis (sJIA)3-6 monthsEfficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemotePediatricsRheumatology

INZ-701 for ENPP1 and ABCC6 Deficiency

We are studying the long-term safety of INZ-701 in patients with ENPP1 and ABCC6 deficiencies. This trial will help us understand how the drug works over time and its effects on certain blood markers.

Pseudoxanthoma ElasticumEctonucleotide Pyrophosphatase/Phosphodiesterase 1 DeficiencyGeneralized Arterial Calcification of InfancyEfficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteDermatologyInternal Medicine

Migraine Treatment in Kids: Rimegepant Study

We are studying the effectiveness of rimegepant for treating migraines in children and adolescents aged 6 to under 18. The goal is to see if it helps relieve pain and other symptoms better than a placebo.

Migraine3-6 monthsConfirmation phase (III)≤5 visits Investigational Medicines Partially RemoteNeurologyPediatrics

Migraine Treatment: Rimegepant for Kids and Teens

We are studying the safety of rimegepant for treating migraines in children and adolescents aged 6 to under 18. This trial will help us understand how well the medication works and if there are any side effects.

Migraine1-2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteNeurology

Non-Transfusion-Dependent Thalassemia: Mitapivat Study

We are studying whether Mitapivat can improve anemia in people with non-transfusion-dependent alpha or beta thalassemia. This trial compares the medication to a placebo to evaluate its effects.

Non-Transfusion Dependent Thalassemia3-6 monthsConfirmation phase (III)6-10 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteHematology

Advanced Solid Tumors: VERT-002 Study

We are studying a new anticancer drug, VERT-002, for patients with advanced solid tumors, including lung cancer with MET alterations. The trial aims to assess its safety and how well it may work.

Metastatic Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncology

Microvillus Inclusion Disease: Crofelemer Study

We are testing the safety and effects of a new oral solution, Crofelemer, in children with Microvillus Inclusion Disease. The study aims to see if it can help reduce symptoms and improve health compared to a placebo.

Microvillous Inclusion Disease6-12 monthsEfficacy phase (II)Investigational Medicines Partially RemoteGastroenterologyPediatrics

Kidney Health: CO2 Injection in Vascular Procedures

We are testing a new method using Carbon Dioxide instead of traditional contrast media for patients at risk of kidney injury during vascular interventions. This study aims to see if it can help prevent serious kidney problems after the procedure.

Peripheral Arterial Disease (PAD)>2 yearsConfirmation phase (III)≤5 visits No Placebo Investigational Medicines Partially RemoteCardiologyNephrology

Shingrix Vaccine: Safety in Psoriasis and Psoriatic Arthritis

We are studying the safety and immune response of the Shingrix vaccine in patients with psoriasis or psoriatic arthritis. Our goal is to see how the vaccine affects disease activity and to monitor any side effects.

Psoriatic ArthritisPsoriasis Vulgaris>2 yearsMonitoring phase (IV)No Placebo Standard Medicines Partially RemoteAllergologyDermatology

Primary Adrenal Insufficiency: Plenadren vs. Cortisone

We are investigating how treatment with Plenadren affects quality of life compared to cortisone in individuals aged 16-80 newly diagnosed with primary adrenal insufficiency.

Primary Adrenal Insufficiency>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteEndocrinology

Severe Alcohol-Associated Hepatitis: INT-787 Study

We are testing a new medication, INT-787, for individuals with severe alcohol-associated hepatitis. The goal is to see if it can help slow down the progression of this serious liver disease.

Alcoholic Hepatitis3-6 monthsEfficacy phase (II)6-10 visits Investigational Medicines Partially RemoteHepatologyInternal Medicine

Advanced Breast Cancer: PF-07220060 with Letrozole

We are studying a new medicine, PF-07220060, combined with letrozole for adults with HR-positive, HER2-negative advanced breast cancer. This trial compares its effectiveness to standard treatments in patients who haven't had prior systemic therapy.

Advanced/Metastatic Breast CancerConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncology

Ovarian Cancer: Continued Treatment with Olaparib

We are providing ongoing treatment with Olaparib for patients who have benefited from it in a previous study. This trial focuses on monitoring safety while allowing continued access to the medication.

Ovarian CancerBreast CancerProstate Cancer>2 yearsConfirmation phase (III)≤5 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteOncology

ENPP1 Deficiency: INZ-701 Study

We are investigating whether the drug INZ-701 can help infants with ENPP1 deficiency by improving survival and preventing heart and respiratory problems. The study aims to see if it can also support physical growth and reduce artery issues.

Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency1-2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteCardiologyPediatrics

Non-Small Cell Lung Cancer: Acasunlimab and Pembrolizumab Study

We are evaluating a new combination treatment for patients with advanced non-small cell lung cancer who have already received other therapies. The goal is to see if this combination works better than the standard treatment, docetaxel.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncology

Search Clinical Trials in the European Union